Literature DB >> 17451812

Human gammadelta T lymphocytes strip and kill tumor cells simultaneously.

Julie Gertner1, Aurélie Wiedemann, Mary Poupot, Jean-Jacques Fournié.   

Abstract

When human gammadelta lymphocytes bind to tumor cells for killing, they also strip their membrane for unknown reasons. Here we investigated this topic using the model of human gammadelta lymphocytes co-incubated with anaplastic large cell lymphomas, a group of tumors with cytolytic T or null lineage. By using flow cytometry and live cell imaging, we show that as soon as both cells were in contact, the TCR-mediated activation of gammadelta lymphocytes simultaneously triggered their secretion of lytic granules and stripping of lymphoma cell membranes, and both activities continued even after their cell death. However reciprocally in such conjugates, resistant lymphoma failed to strip gammadelta cells and to kill them by untargeted secretion of their own lytic granules. This indicated that secretion of lytic granules and target membrane stripping are associated in lytic cell conjugates, and that gammadelta T lymphocytes strip and kill their targets simultaneously.

Entities:  

Mesh:

Year:  2007        PMID: 17451812     DOI: 10.1016/j.imlet.2007.03.002

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  12 in total

1.  γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.

Authors:  Mounia Sabrina Braza; Bernard Klein; Geneviève Fiol; Jean-François Rossi
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

2.  Enhanced development of CD4+ gammadelta T cells in the absence of Itk results in elevated IgE production.

Authors:  Qian Qi; Mingcan Xia; Jianfang Hu; Elizabeth Hicks; Archana Iyer; Na Xiong; Avery August
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

3.  BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia.

Authors:  Audrey Benyamine; Aude Le Roy; Emilie Mamessier; Julie Gertner-Dardenne; Céline Castanier; Florence Orlanducci; Laurent Pouyet; Armelle Goubard; Yves Collette; Norbert Vey; Emmanuel Scotet; Remy Castellano; Daniel Olive
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

4.  BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC).

Authors:  Audrey Benyamine; Céline Loncle; Etienne Foucher; Juan-Luis Blazquez; Céline Castanier; Anne-Sophie Chrétien; Mauro Modesti; Véronique Secq; Salem Chouaib; Meritxell Gironella; Elena Vila-Navarro; Giuseppe Montalto; Jean-Charles Dagorn; Nelson Dusetti; Juan Iovanna; Daniel Olive
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

5.  Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.

Authors:  Swati Dhar; Shubhada V Chiplunkar
Journal:  Cancer Immun       Date:  2010-11-12

6.  Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma.

Authors:  Cédric Rossi; Pauline Gravelle; Emilie Decaup; Julie Bordenave; Mary Poupot; Marie Tosolini; Don-Marc Franchini; Camille Laurent; Renaud Morin; Jean-Michel Lagarde; Loïc Ysebaert; Laetitia Ligat; Christine Jean; Ariel Savina; Christian Klein; Alba Matas Céspedes; Patricia Perez-Galan; Jean-Jacques Fournié; Christine Bezombes
Journal:  Oncoimmunology       Date:  2018-12-17       Impact factor: 8.110

7.  BTN3A Targeting Vγ9Vδ2 T Cells Antimicrobial Activity Against Coxiella burnetii-Infected Cells.

Authors:  Laetitia Gay; Soraya Mezouar; Carla Cano; Etienne Foucher; Mélanie Gabriac; Marie Fullana; Loui Madakamutil; Jean-Louis Mège; Daniel Olive
Journal:  Front Immunol       Date:  2022-06-27       Impact factor: 8.786

8.  Assessing in vitro and in vivo Trogocytosis By Murine CD4+ T cells.

Authors:  Jim Reed; Scott A Wetzel
Journal:  Bio Protoc       Date:  2020-05-05

9.  Tumor-activated TCRγδ⁺ T cells from gastric cancer patients induce the antitumor immune response of TCRαβ⁺ T cells via their antigen-presenting cell-like effects.

Authors:  Chaoming Mao; Xiao Mou; Yuepeng Zhou; Guoyue Yuan; Chengcheng Xu; Hongli Liu; Tingting Zheng; Jia Tong; Shengjun Wang; Deyu Chen
Journal:  J Immunol Res       Date:  2014-03-31       Impact factor: 4.818

10.  Self-activation of Vγ9Vδ2 T cells by exogenous phosphoantigens involves TCR and butyrophilins.

Authors:  Chloé Laplagne; Laetitia Ligat; Juliet Foote; Frederic Lopez; Jean-Jacques Fournié; Camille Laurent; Salvatore Valitutti; Mary Poupot
Journal:  Cell Mol Immunol       Date:  2021-06-28       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.